11 min read
Monthly FDA Guidance and Regulatory News Review - September 2026
This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...
Meet Veristat in Rome at the Meeting on the Med Conference 2024, 9-11 April 2024
With nearly 30 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.
If you are transitioning your compound into clinical trials, you need the right partner to guide your planning and decision-making. Whether you are preparing your IND/CTA, or you are looking to recruit patients quickly to get your early phase trials running, or just need medical writing or biostatistical support for your programs – Veristat can help.
The Science-First CRO.™
The scientific full service CRO and consultancy integrating strategic planning, regulatory strategy, and clinical trial execution to rapidly advance your complex or novel therapies. In the past five years, our team members have supported more than 350 clinical trials and consulting projects for rare diseases and have worked on more than 40+ US and European regulatory marketing applications – 30 of which have been approved so far.
Don't miss this opportunity to connect with us.
Schedule A Meeting
Veristat team members will be at the venue, ready to listen to your needs and share more about Veristat’s expertise:
John Balser, PhD, Founder, President & Chief Statistical Officer
Barbara Balser, VMD, Founder, Executive Vice President & Chief Scientific Officer
Rachel Page, Chief Commercial Officer
Patrick Flanagan, Chief Executive Officer
You can arrange a meeting by completing the form on the right side of this page. Discover how we can assist you in progressing in your upcoming project
Conference Details
Website: MEETING ON THE MED
Schedule A Meeting
Meet with us at the CELL & GENE MEETING ON THE MED 2024 by filling out the form below.
8 min read
Monthly FDA Guidance and Regulatory News Review - August 2026
Sep 21, 2026 Veristat Blog
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...